Longevity & AgingResearch PaperOpen Access

GDF-15 predicts death and bleeding after heart attack but cannot diagnose one

A narrative review finds the stress hormone GDF-15 flags mortality, heart failure and bleeding risk after ACS, but it is not a diagnostic test and has no proven management use.

Wednesday, November 18, 2026 0 views
Published in Int J Mol Sci
Glowing GDF-15 protein dimer binding a receptor, with a faint ECG trace and blood sample tube in the background

Summary

GDF-15 is a stress-induced signaling protein that rises with ischemia, inflammation, kidney disease, frailty and aging. This narrative review of acute coronary syndrome (ACS) literature concludes that it is a poor test for diagnosing heart attack (AUC about 0.69 vs 0.96 for troponin) but a strong prognostic marker. Higher levels track with all-cause and cardiovascular death, heart failure and major bleeding, and less specifically with recurrent heart attack. In a 4,779-patient emergency cohort, 90-day and 5-year mortality C-indices were 0.86 and 0.84. Evidence is associational. There are no validated thresholds, and no trial shows GDF-15-guided care improves outcomes, so routine use to guide antiplatelet therapy is unsupported. The provided text is truncated before the incremental-value results.

0:00--:--

Detailed Summary

Troponin tells clinicians whether the heart muscle is injured, but not how biologically vulnerable the patient is. GDF-15 is a stress-response protein induced by ischemia, oxidative stress, inflammation, mitochondrial dysfunction and aging, so it may capture that residual risk. This review asks whether it adds clinical value in acute coronary syndromes (ACS) or only another number.

This is a purposive narrative review. It searched PubMed, Web of Science and Scopus to June 2026 and did not use PRISMA, dual screening or formal risk-of-bias scoring. No pooling was done because populations, assays, sampling times and endpoints differed. Evidence was weighted qualitatively: individual-participant meta-analyses and trial biomarker substudies first, small single-center studies for hypothesis generation only.

On mechanism, GDF-15 is released as a processed dimer and induced by the integrated stress response (eIF2α-ATF4-CHOP) and by p53, NF-κB and HIF-1α. Its established endocrine receptor, GFRAL-RET, sits in the hindbrain and drives appetite suppression and weight loss. In mice, GDF-15 deficiency produced larger infarcts after coronary ligation, and recombinant protein protected cultured cardiomyocytes via PI3K/Akt. The authors stress that this cardiac effect is a putative, receptor-unresolved finding, and it does not make GDF-15 a therapeutic target in ACS. Levels also climb steeply with age (median about 537 pg/mL in men under 30 vs about 2152 pg/mL at 80+), and correlate with frailty.

Diagnostically, GDF-15 performs poorly, with an AUC of 0.69 for index MI versus 0.96 for hs-troponin T in early work. In the APACE cohort (4,779 emergency chest pain patients), it also had an AUC of 0.69 for NSTE-MI but strong mortality discrimination. Prognostically, higher levels are linked to death, heart failure and bleeding. In PLATO, the signal was stronger for death and bleeding than for recurrent MI. An individual-participant meta-analysis of 53,486 patients found no significant association with future MI in acute ACS (HR 0.98, 0.90–1.06). Historical research bands (below 1200, 1200–1800, above 1800 pg/mL) are orientation only.

Caveats: these are observational associations, not outcomes from GDF-15-guided care. Levels are confounded by age, kidney function, heart failure, diabetes and cancer. Assays and sampling times differ, and no validated ACS thresholds exist. Needed next are calibration, decision-curve and health-economic evidence, and trials showing management changes improve outcomes.

Key Findings

  • GDF-15 diagnoses MI poorly: AUC 0.69 versus 0.96 for hs-troponin T, so it should not replace ECG and troponin algorithms.
  • In 4,779 emergency chest pain patients, GDF-15 predicted all-cause mortality (C-index 0.86 at 90 days, 0.84 at 5 years).
  • Associations are strongest for all-cause and cardiovascular death, heart failure and bleeding, and weaker for recurrent MI (pooled HR 0.98, 0.90–1.06, 53,486 patients).
  • Mouse and cell work suggests GDF-15 may be cardioprotective, but the receptor is unresolved and this is not evidence for a therapeutic target.
  • No validated ACS thresholds, and no trial shows GDF-15-guided antiplatelet therapy or care improves outcomes.

Methodology

Purposive narrative review of PubMed, Web of Science and Scopus to June 2026, without PRISMA, dual screening or formal risk-of-bias scoring. Studies were weighted qualitatively and not pooled because of heterogeneity. The supplied text is cut off before the incremental-value results, so reclassification data are not summarized here.

Study Limitations

The conclusions rest on observational associations from a non-systematic review, with possible selection bias and confounding by age, renal function and comorbidity. Assays, sampling times and endpoints are inconsistent, and there are no standardized thresholds or decision-impact trials. Mechanistic cardioprotection data come from small preclinical studies with an unresolved receptor.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: